Insmed Incorporated (INSM)
NASDAQ: INSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 102.00 +0.26%
INSM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.22B
- Forward P/E
- 131.31
- EPS (TTM)
- -$4.16
- Dividend yield
- None
- 52-week range
- 90.39 – 212.75
- Day range
- 101.60 – 104.80
- Volume / Avg
- 3.16M / 2.56M
- Beta
- —
- Shares outstanding
- 218.38M
- Next earnings
- Oct 29, 2026
52-week range
INSM stock today
Shares of Insmed (INSM) finished lower on Oct 7 at $101.74, a drop of 3.32% or $3.49 per share, versus the S&P 500's 0.22% decline. Shares are 52.2% below their 52-week high of $212.75, set on Dec 2, 2025 and 12.6% above the 52-week low of $90.39, near the bottom of the past year's range. INSM is down 41.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 37.3%.
Insmed has posted a net loss over the last twelve months (EPS of -$4.16), so its P/E ratio is not meaningful. Insmed's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Insmed
Company profileInsmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. William H. Lewis J.D., M.B.A.
- Headquarters
- Bridgewater, NJ
- Employees
- 1,664
- Website
- insmed.com
Financial highlights
Full financialsIn fiscal 2025, Insmed generated $606.4 million in revenue, up 66.7% from fiscal 2024, its 8th consecutive year of revenue growth. Insmed reported a net loss of $1.28 billion, compared with a loss of $913.8 million a year earlier. Gross margin was 79.7% (up from 76.4%) and operating margin -205.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $606.42M | $363.71M | $305.21M | $245.36M | $188.46M |
| Growth | +66.73% | +19.17% | +24.39% | +30.19% | +14.63% |
| Net income | $-1.28B | $-913.77M | $-749.57M | $-481.53M | $-434.65M |
| EPS (diluted) | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 |
Analyst forecast
ForecastConsensus (24 analysts)
strong_buy
Avg. price target
$197.74+94.36%
- Strong buy 5
- Buy 19
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $-0.37
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.06 vs —
INSM news
All INSM newsInsmed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs INSM |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs INSM |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs INSM |
| VTRSViatris Inc. | 17.49 | -0.29% | $20.09B | vs INSM |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs INSM |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs INSM |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs INSM |
| JAZZJazz Pharmaceuticals plc | 231.19 | -0.09% | $15.01B | vs INSM |
Indexes, lists and sector
Insmed stock FAQ
What is Insmed's stock price today?
INSM last traded at $101.74 as of Oct 7, 4:00 PM EDT, down 3.32% on the day. Prices are delayed at least 15 minutes.
Does Insmed pay a dividend?
No. Insmed does not currently pay a regular cash dividend.
When is Insmed's next earnings date?
Insmed is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $-0.37.
Who is Insmed's CEO?
Mr. William H. Lewis J.D., M.B.A. is the chief executive officer of Insmed Incorporated, which has about 1,664 employees.
Has INSM ever split its stock?
Yes. The most recent INSM stock split was a 1-for-10 split on Mar 3, 2011, one of 2 splits on record.
What is the INSM 52-week high?
The 52-week high for INSM is $212.75 and the 52-week low is $90.39. The stock is currently 52.2% below its high.